Navigation Links
Neuralstem updates ALS clinical trial progress
Date:10/19/2010

ROCKVILLE, Maryland, October 18, 2010 Neuralstem, Inc. (NYSE Amex: CUR) updated the progress of its ongoing Phase I human clinical trial of the company's spinal cord stem cells in the treatment of ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia. The company announced that, after reviewing the safety data from the first six non-ambulatory patients, the trial's Safety Monitoring Board has unanimously approved moving to the next group of ALS patients, all of whom will be ambulatory.

"We are pleased with the progress of the trial to date, and look forward to moving directly into more recently-diagnosed patients," commented Dr. Eva Feldman, PhD, MD, Principal Investigator of the trial and a consultant to Neuralstem. Dr. Feldman is Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System.

"We are encouraged by the Board's approval to advance the trial to patients who have an earlier stage of the disease," said Neuralstem's CEO and president, Richard Garr. "While the primary endpoint of the trial is safety, we also hope to see some secondary endpoints showing efficacy. We are grateful to the patients, and their families, for participating in this trial."

The first six patients treated in the trial were non-ambulatory. Of these, the first three received five injections each, unilaterally, in the lumbar region of the spinal cord. The next three received ten injections each, bilaterally in the lumbar region. All of the remaining patients in the trial will be ambulatory, and therefore represent earlier stages of disease progression. Of the ambulatory group, the first three patients will receive five injections each, unilaterally, in the lumbar region. The next three will receive ten injections each, bilaterally, in the lumbar region. After the required FDA approval, the final six patients in the trial will receive injections in the cervical region, representing both a progression of treatment up the spinal cord, as well as into more recently-diagnosed patients.


'/>"/>

Contact: Deanne Eagle
deanneeagle@gmail.com
917-837-5866
Neuralstem, Inc.
Source:Eurekalert

Related medicine news :

1. Neuralstem chief scientific officer to take part in World Stem Cell Summit plenary session
2. Neuralstem stem cells survive and differentiate into neurons in rats with stroke
3. Neuralstem files FDA application for first chronic spinal cord injury stem cell trial
4. Neuralstem updates clinical trial progress
5. New "howsthepatient" iPhone App Provides a Simple, Seamless Way to Send Health Updates to Friends and Family
6. FDA Updates Import Alert 71-04 for Salmonella Contaminated Animal Feeds: Many Non-U.S. Firms Affected According to FDAImports.com, LLC
7. Clone Systems, Inc. Updates PCI Solutions for Level 1 & 2 Merchants
8. American Traveler Offers New Healthcare Jobs Hourly, Updates Via Job RSS & Twitter
9. Global Medical Products (GMDP) Selects Mina Mar Group as Its Corporate Advisor And Updates
10. Sunquest Announces Major Software Updates and Enhancements
11. New clinical trial explores role of vitamin D in preventing esophageal cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... Many RNA ... regulatory principles, the research team developed expressRNA, a web platform encompassing computational tools ... reveals at nucleotide resolution the ‘RNA maps’, which demonstrate that RBPs bind to ...
(Date:6/20/2017)... ... 2017 , ... Uniform Advantage (UA), a multi-channel retailer of medical ... create tailored looks and athleisure-inspired outfits. UA Flex fabric is breathable, wrinkle resistant and ... With trendy looks hitting the medical community, UA Flex is for the medical professional ...
(Date:6/20/2017)... ... June 20, 2017 , ... BrightStar Care Centerville/South Dayton, a ... the Joint Commission, which accredits and certifies nearly 21,000 healthcare organizations and programs ... a symbol of quality that reflects an organization’s commitment to meeting certain performance ...
(Date:6/20/2017)... ... 20, 2017 , ... Uniworld Boutique River Cruise Collection recently gave ... boutique ship, S.S. Joie de Vivre . What really sets this ship apart ... River and designed small enough to dock directly in Paris. With The Cruise Web’s ...
(Date:6/20/2017)... ... June 20, 2017 , ... International water ... The Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health ... world’s water crisis and how it affects the human eyes. , According ...
Breaking Medicine News(10 mins):
(Date:5/26/2017)... BARBARA, Calif. , May 25, 2017  In ... United States , Direct Relief is working with ... overdose-reversing Naloxone available at no cost to community health ... other nonprofit providers nationwide. "Pfizer has ... access to medicines and ensuring patient safety through educational ...
(Date:5/22/2017)... 2017  Lilac Corp, the company that sells ... of a new website . The website ... clinical study that showed surprising clearance of the ... individuals suffering from HPV warts, precancerous, or cancerous ... no other treatments that clear the virus. Specifically, ...
(Date:5/18/2017)... WHIPPANY, N.J. , May 17, 2017  Bayer ... growing oncology portfolio will be presented at the 53 ... Clinical Oncology (ASCO), taking place June 2-6 in ... being presented at ASCO span prostate, colorectal, liver and ... subgroup analysis from the Phase II CHRONOS-1 trial of ...
Breaking Medicine Technology: